Extensive genomic profiling has proven better reliability in identifying colorectal patients with resistance-associated KRAS alterations, melanoma patients with responsive BRAF mutations, lung cancer patients with therapy-associated ALK rearrangements, and ovarian cancer patients with somatic BRCA1/2 alterations who may benefit from PARP inhibitors, than the respective traditional approaches [43,44,45,46]. This evidence concerns the gene ALK and ovarian carcinoma.